Basic information Safety Supplier Related
ChemicalBook >  Product Catalog >  API >  Antineoplastic agents >  Natural sources of antineoplastic >  Teniposide

Teniposide

Basic information Safety Supplier Related

Teniposide Basic information

Product Name:
Teniposide
Synonyms:
  • (5R,5aα)-5α,8,8aβ,9β-Tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-9-[[4-O,6-O-[(R)-2-thienylmethylene]-β-D-glucopyranosyl]oxy]furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one
  • 4'-Demethylepipodophyllotoxin-9-(4,6-O-2-thenylidene β-D-glucopyranoside)
  • 4’-Demethylepipodophyllotoxin9-(4,6-o-2-thenylidene-
  • 4'-Demethylepipodophyllotoxin thenylidene glucoside
  • Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-o-2-thienylidene-.beta.-D-glucopyranoside)
  • Furo[3',4':6,7]naphtho[2,3-D]-1,3-dioxol-6(5ah)-one, 5,8,8A,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-9-[[4,6-o-(2-thienylmethylene)-.beta.-D-glucopyranosyl]oxy]-, [5R-(5.alpha.,5A.beta.,8A.alpha.,9.beta.)]-
  • (10R,11R,15R,16S)-16-{[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-(thiophen-2-yl)-hexahydro-2H-pyrano[3,2-d][1,3]dioxin-6-yl]oxy}-10-(4-hydroxy-3,5-diMethoxyphenyl)-4,6,13-trioxatetracyclo[7.7.0.0^{3,7}.0^{11,15}]hexadeca-1,3(7),8-trien-12-one
  • Teniposide(VuMon)
CAS:
29767-20-2
MF:
C32H32O13S
MW:
656.65
EINECS:
249-831-2
Product Categories:
  • Carbohydrates & Derivatives
  • Chiral Reagents
  • Heterocycles
  • Intermediates & Fine Chemicals
  • Pharmaceuticals
  • Isotope Labelled Compounds
  • Active Pharmaceutical Ingredients
  • VUMON
  • API
  • Inhibitors
  • 29767-20-2
Mol File:
29767-20-2.mol
More
Less

Teniposide Chemical Properties

Melting point:
244-247°C
alpha 
D20 -107° (9:1 chloroform/methanol)
Boiling point:
650.86°C (rough estimate)
Density 
1.2568 (rough estimate)
refractive index 
1.5530 (estimate)
storage temp. 
-20°C
solubility 
DMSO: soluble10mg/mL, clear
pka
10.13(at 25℃)
form 
powder
color 
white to beige
optical activity
[α]/D -100 to -115°, c = 1 in chloroform/methanol (9:1)
λmax
283nm(MeOH)(lit.)
Merck 
14,9145
Stability:
Hygroscopic
CAS DataBase Reference
29767-20-2(CAS DataBase Reference)
IARC
2A (Vol. 76) 2000
More
Less

Safety Information

Hazard Codes 
Xi,T
Risk Statements 
36/37/38-45
Safety Statements 
26-36-45-53
RIDADR 
UN 2811 6.1 / PGIII
WGK Germany 
3
RTECS 
KC0180000
HS Code 
29349990
Hazardous Substances Data
29767-20-2(Hazardous Substances Data)
Toxicity
LD50 intraperitoneal in mouse: 29570ug/kg
More
Less

Teniposide Usage And Synthesis

Chemical Properties

White Solid

Originator

Vehem,Sandoz,France,1976

Uses

Teniposide is a podophyllotoxin derivative that causes dose-dependent single- and double-stranded breaks in DNA by inhibiting topoisomerase II. Its cytostatic effects are related to its ability to stabilize the DNA-topoisomerase II complex during DNA replication, inducing DNA damage and cellular apoptosis. Teniposide has been widely used in the treatment of various cancers including, small cell lung cancer, malignant lymphoma, breast cancer, oral squamous cell carcinoma, and acute lymphoblastic leukemia.

Uses

A labelled semi-synthetic derivative of Podophyllotoxin. Antineoplastic.

Uses

A semi-synthetic derivative of Podophyllotoxin. Antineoplastic.

Indications

Teniposide (VM-26, Vumon) is closely related to etoposide in structure, mechanisms of action and resistance, and adverse effects. It is more lipophilic and approximately threefold more potent than etoposide. Its major uses have been in pediatric cancers, particularly in acute lymphoblastic leukemias.

Definition

ChEBI: A furonaphthodioxole that is a synthetic derivative of podophyllotoxin with anti-tumour activity; causes single- and double-stranded breaks in DNA and DNA-protein cross-links and prevents repair by topoisomerase II binding.

Manufacturing Process

10 ml of pure thiophene-2-aldehyde and 0.25 g of anhydrous zinc chloride are American Home Products Corporation; British Patent 1,022,642; March 16, 1966
American Home Products Corporation; British Patent 1,022,645; March 16, 1966
Bell, S.C.; British Patent 1,057,492; February 1, 1967; assigned to American Home Products Corporation

brand name

Vumon (Bristol-Myers Squibb).

Therapeutic Function

Antineoplastic

General Description

Teniposide is available in 50-mg ampules with Cremophor ELfor IV administration in the treatment of acute lymphoblasticleukemia (ALL). The agent is more potent as an inhibitor oftopoisomerase II. The pharmacokinetics of teniposide issimilar to that of etoposide; however, the more lipophilic teniposideis more highly protein bound (99%) and less isexcreted unchanged in the urine (10%–20%). There is alsogreater overall metabolism of teniposide; however, CYP3A4-mediated conversion to the active catechol is slower comparedwith etoposide. Elimination occurs primarily in the urine witha terminal elimination half-life of 5 hours.

Biochem/physiol Actions

Teniposide (VM-26) is a Topoisomerase II inhibitor with antitumor activity. Teniposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA, inducing breaks in double stranded DNA and preventing repair.

Clinical Use

Teniposide is used in combination with other agents for the treatment of refractory childhood acute lymphoblastic leukemia.

Safety Profile

Poison by intraperitoneal and subcutaneous routes. An experimental teratogen. Human systemic effects by ingestion and intravenous route: anorexia, nausea or vomiting, leukopenia, agranulocytosis and aplastic anemia of the blood, bone marrow changes, and hair changes. Experimental reproductive effects. Human mutation data reported. When heated to decomposition it emits very toxic fumes of SOx.

Synthesis

Teniposide, [5R-(5|á,5a|?,8a|á,9|?)]-9-[4,6-O-(2-thienylmethylene)-|?-D-glucopyranosyl)oxy]- 5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)furo[3,4: 6,7]-naphtho[2,3-d]-1,3-dioxol-6(5aH)-one (30.4.9), is basically synthesized by an analogous scheme from 4-benzyloxy-4-desmethylepipodophyllotoxin (30.4.6), which is esterified by 2,3,4,6- tetra-O-acetyl-|?-D-glucose in the presence of boron trifluoride etherate, giving a glycoside 30.4.7. The acetyl and benzyloxycarbonyl protecting groups in this molecule are removed by succesive use of zinc acetate and sodium methoxide, and then by subsequent hydrogen reduction, which forms the diol 30.4.8. The resulting diol is then transformed into the corresponding acetal 2-formylthiophene, which is the desired teniposide (30.4.9) .

storage

Store at -20°C

TeniposideSupplier

J & K SCIENTIFIC LTD.
Tel
010-82848833 400-666-7788
Email
jkinfo@jkchemical.com
3B Pharmachem (Wuhan) International Co.,Ltd.
Tel
821-50328103-801 18930552037
Email
3bsc@sina.com
Chembest Research Laboratories Limited
Tel
+86-21-20908456
Email
sales@BioChemBest.com
TCI (Shanghai) Development Co., Ltd.
Tel
021-67121386
Email
Sales-CN@TCIchemicals.com
LGM Pharma
Tel
1-(800)-881-8210
Email
inquiries@lgmpharma.com